Antimalarial treatment in infants

References

• World Health Organization (WHO). World malaria report. WHO, Geneva, 2021.
   Google Scholar
• D’Alessandro U, Ubben D, Hamed K, et al. Malaria in infants aged less than six months - is it an area of unmet medical need? Malar J. 2012;11(1):400.
   PubMedGoogle Scholar
• Botwe AK, Oppong FB, Gyaase S, et al. Determinants of the varied profiles of Plasmodium falciparum infections among infants living in Kintampo, Ghana. Malar J. 2021;20(1):240.
   PubMedGoogle Scholar
• Botwe AK, Owusu-Agyei S, Asghar M, et al. Profiles of Plasmodium falciparum infections detected by microscopy through the first year of life in Kintampo a high transmission area of Ghana. PLoS One. 2020;15(10):e0240814.
   PubMedGoogle Scholar
• Ceesay SJ, Koivogui L, Nahum A, et al. Malaria prevalence among young infants in different transmission settings, Africa. Emerg Infect Dis. 2015;21(7):1114–1121.
   PubMed Web of Science ®Google Scholar
• Natama HM, Rovira-Vallbona E, Some MA, et al. Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study. Malar J. 2018;17(1):163.
   PubMedGoogle Scholar
• World Health Organization (WHO). Guidelines for malaria. Geneva: WHO; 2021.
   Google Scholar
• Wanzira H, Kakuru A, Arinaitwe E, et al. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis. 2014;59(4):509–516.
   PubMed Web of Science ®Google Scholar
• Afolabi BM, Rabiu KA, Sanyaolu NO. Malaria in the first 6 months of life in urban African infants with anemia. Am J Trop Med Hyg. 2001;65(6):822–827.
   PubMed Web of Science ®Google Scholar
• Binka F, Morris SS, Ross DA. Patterns of malaria morbidity and mortality in children in northern Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1994;88(4):381–385.
   PubMed Web of Science ®Google Scholar
• Klein Klouwenberg PM, Oyakhirome S, Schwarz NG, et al. Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months. Acta Trop. 2005;95(2):81–85.
   PubMed Web of Science ®Google Scholar
• Carneiro I, Roca-Feltrer A, Griffin JT, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One. 2010;5(2):e8988.
   PubMed Web of Science ®Google Scholar
• Danwang C, Bigna JJ, Nzalie RNT, et al. Epidemiology of clinical congenital and neonatal malaria in endemic settings: a systematic review and meta-analysis. Malar J. 2020;19(1):312.
   PubMed Web of Science ®Google Scholar
• Dobbs KR, Dent AE. Plasmodium malaria and antimalarial antibodies in the first year of life. Parasitology. 2016;143(2):129–138.
   PubMed Web of Science ®Google Scholar
• Bilal JA, Malik EE, Al-Nafeesah A, et al. Global prevalence of congenital malaria: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;252:534–542.
   PubMed Web of Science ®Google Scholar
• Menendez C, Mayor A. Congenital malaria: the least known consequence of malaria in pregnancy. Semin Fetal Neonatal Med. 2007;12(3):207–213.
   PubMed Web of Science ®Google Scholar
• Alonso S, Vidal M, Ruiz-Olalla G, et al. HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women. J Infect. 2021;82(4):45–57.
   PubMed Web of Science ®Google Scholar
• Agbota G, Accrombessi M, Cottrell G, et al. Increased risk of malaria during the first year of life in small-for-gestational-age infants: a longitudinal study in Benin. J Infect Dis. 2019;219(10):1642–1651.
   PubMed Web of Science ®Google Scholar
• Sotimehin SA, Runsewe-Abiodun TI, Oladapo OT, et al. Possible risk factors for congenital malaria at a tertiary care hospital in Sagamu, Ogun State, South-West Nigeria. J Trop Pediatr. 2008;54(5):313–320.
   PubMed Web of Science ®Google Scholar
• Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395–404.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167.
   PubMed Web of Science ®Google Scholar
• Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19(4):262–276.
   PubMedGoogle Scholar
• White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57(12):5792–5807.
   PubMed Web of Science ®Google Scholar
• White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41(7):1413–1422.
   PubMed Web of Science ®Google Scholar
• White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37(2):105–125.
   PubMed Web of Science ®Google Scholar
• Simpson JA, Jamsen KM, Price RN, et al. Towards optimal design of anti-malarial pharmacokinetic studies. Malar J. 2009;8(1):189.
   PubMedGoogle Scholar
• Verrest L, Wilthagen EA, Beijnen JH, et al. Influence of malnutrition on the pharmacokinetics of drugs used in the treatment of poverty-related diseases: a systematic review. Clin Pharmacokinet. 2021;60(9):1149–1169.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647–1657.
   PubMed Web of Science ®Google Scholar
• Dondorp A, Nosten F, Stepniewska K, et al. South east asian quinine artesunate malaria trial g: artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366(9487):717–725.
   PubMed Web of Science ®Google Scholar
• Cao XT, Bethell DB, Pham TP, et al. Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Trans R Soc Trop Med Hyg. 1997;91(3):335–342.
   PubMed Web of Science ®Google Scholar
• Sinclair D, Donegan S, Isba R, et al. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;2012(6):CD005967
   Google Scholar
• Zaloumis SG, Tarning J, Krishna S, et al. Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT Pharmacometrics Syst Pharmacol. 2014;3(11):e145.
   PubMedGoogle Scholar
• Hendriksen IC, Mtove G, Kent A, et al. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Ther. 2013;93(5):443–450.
   PubMed Web of Science ®Google Scholar
• Kitabi E, Bensman TJ, Earp JC, et al. Effect of body weight and age on the pharmacokinetics of dihydroartemisinin: food and drug administration basis for dose determination of artesunate for injection in pediatric patients with severe malaria. Clin Infect Dis. 2021;73(5):903–906.
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Adegnika AA, Hounkpatin AB, et al. Intramuscular artesunate for severe malaria in African children: a multicenter randomized controlled trial. PLoS Med. 2016;13(1):e1001938.
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Taylor T, Issifou S, et al. A simplified intravenous artesunate regimen for severe malaria. J Infect Dis. 2012;205(2):312–319.
   PubMed Web of Science ®Google Scholar
• Fanello C, Onyamboko M, Lee SJ, et al. Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. BMC Infect Dis. 2017;17(1):575.
   PubMedGoogle Scholar
• Rolling T, Agbenyega T, Issifou S, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria–a double-center prospective study. J Infect Dis. 2014;209(12):1921–1928.
   PubMed Web of Science ®Google Scholar
• Krishna S, Planche T, Agbenyega T, et al. Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob Agents Chemother. 2001;45(2):509–516.
   PubMed Web of Science ®Google Scholar
• Okebe J, Eisenhut M. Pre-referral rectal artesunate for severe malaria. Cochrane Database Syst Rev. 2014;(5):CD009964.
   PubMed Web of Science ®Google Scholar
• Gomes MF, Faiz MA, Gyapong JO, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet. 2009;373(9663):557–566.
   PubMed Web of Science ®Google Scholar
• Grobusch MP. Early rectal artesunate administration: a life-saver in remote areas? Future Microbiol. 2009;4(4):397–400.
   PubMed Web of Science ®Google Scholar
• Esu EB, Effa EE, Opie ON, et al. Artemether for severe malaria. Cochrane Database Syst Rev. 2019;6: CD010678 doi:10.1002/14651858.CD010678.pub3
   PubMedGoogle Scholar
• Bobossi-Serengbe G, Gody JC, Fioboy R, et al. [Comparison of the effectiveness of artemether and quinine for treatment of severe malaria in children, Bangui, Central African Republic]. Bull Soc Pathol Exot. 2015;108(2):107–111.
   PubMedGoogle Scholar
• Huda SN, Shahab T, Ali SM, et al. A comparative clinical trial of artemether and quinine in children with severe malaria. Indian Pediatr. 2003;40(10):939–945.
   PubMedGoogle Scholar
• Minta D, Sissoko M, Sidibe I, et al. Efficacy and safety of artemether in the treatment of severe end complicated malaria in Mali. Mali Med. 2005;20(1–2):28–32.
   PubMedGoogle Scholar
• Murphy SA, Mberu E, Muhia D, et al. The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans R Soc Trop Med Hyg. 1997;91(3):331–334.
   PubMed Web of Science ®Google Scholar
• Mithwani S, Aarons L, Kokwaro GO, et al. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. Br J Clin Pharmacol. 2004;57(2):146–152.
   PubMed Web of Science ®Google Scholar
• Aceng JR, Byarugaba JS, Tumwine JK. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ. 2005;330(7487):334.
   PubMedGoogle Scholar
• Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet. 1996;30(4):263–299.
   PubMed Web of Science ®Google Scholar
• Schapira A, Solomon T, Julien M, et al. Comparison of intramuscular and intravenous quinine for the treatment of severe and complicated malaria in children. Trans R Soc Trop Med Hyg. 1993;87(3):299–302.
   PubMed Web of Science ®Google Scholar
• Achan J, Byarugaba J, Barennes H, et al. Rectal versus intravenous quinine for the treatment of childhood cerebral malaria in Kampala, Uganda: a randomized, double-blind clinical trial. Clin Infect Dis. 2007;45(11):1446–1452.
   PubMed Web of Science ®Google Scholar
• Assimadi JK, Gbadoe AD, Agbodjan-Djossou O, et al. [Diluted injectable quinine in the intramuscular and intrarectal route: comparative efficacity and tolerance in malaria treatment for children]. Med Trop (Mars). 2002;62(2):158–162.
   PubMedGoogle Scholar
• Eisenhut M, Omari A, MacLehose HG. Intrarectal quinine for treating Plasmodium falciparum malaria: a systematic review. Malar J. 2005;4(1):24.
   PubMedGoogle Scholar
• Hendriksen IC, Maiga D, Lemnge MM, et al. Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. Antimicrob Agents Chemother. 2013;57(2):775–783.
   PubMed Web of Science ®Google Scholar
• Saeheng T, Na-Bangchang K. Clinical pharmacokinetics of quinine and its relationship with treatment outcomes in children, pregnant women, and elderly patients, with uncomplicated and complicated malaria: a systematic review. Malar J. 2022;21(1):41.
   PubMed Web of Science ®Google Scholar
• Shann FA, Stace J, Edstein M. Pharmacokinetics of quinine in children. J Pediatr. 1985;106(3):506–510.
   PubMed Web of Science ®Google Scholar
• Krishna S, Nagaraja NV, Planche T, et al. Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother. 2001;45(6):1803–1809.
   PubMed Web of Science ®Google Scholar
• Achan J, Talisuna AO, Erhart A, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10(1):144.
   PubMedGoogle Scholar
• World Health Organization (WHO). Report on antimalarial drug efficacy, resistance and response In.; 2020.
   Google Scholar
• WHO. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. Informal consultation organized by the World Health Organization, with the technical support of the worldwide antimalarial resistance network. Bangkok; 2010.
   Google Scholar
• World Health Organization (WHO). Guidelines for the treatment of malaria. third edition ed. Geneva: World Health Organization; 2015.
   Google Scholar
• Guidi M, Mercier T, Aouri M, et al. Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children. Malar J. 2019;18(1):139.
   PubMedGoogle Scholar
• Djimde AA, Tekete M, Abdulla S, et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2011;55(9):3994–3999.
   PubMed Web of Science ®Google Scholar
• Plucinski MM, Dimbu PR, Macaia AP, et al. Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. Malar J. 2017;16(1):62.
   PubMed Web of Science ®Google Scholar
• Ishengoma DS, Mandara CI, Francis F, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18(1):88.
   PubMedGoogle Scholar
• Zongo I, Compaore YD, Nikiema F, et al. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan Afr Med J. 2020;35:68.
   PubMed Web of Science ®Google Scholar
• Yeka A, Wallender E, Mulebeke R, et al. Comparative efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Ugandan children. J Infect Dis. 2019;219(7):1112–1120.
   PubMed Web of Science ®Google Scholar
• Beavogui AH, Camara A, Delamou A, et al. Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial. Malar J. 2020;19(1):223.
   PubMed Web of Science ®Google Scholar
• Tiono AB, Tinto H, Alao MJ, et al. Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem(R)). Malar J. 2015;14(1):157.
   PubMedGoogle Scholar
• Bassat Q, Gonzalez R, Machevo S, et al. Similar efficacy and safety of artemether-lumefantrine (Coartem(R)) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar J. 2011;10(1):369.
   PubMedGoogle Scholar
• Kloprogge F, Workman L, Borrmann S, et al. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018;15(6):e1002579.
   PubMed Web of Science ®Google Scholar
• Tchaparian E, Sambol NC, Arinaitwe E, et al. Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria. J Infect Dis. 2016;214(8):1243–1251. Study on lumefantrine pharmacokinetics and dosing in infants.
   PubMed Web of Science ®Google Scholar
• Onyamboko MA, Fanello CI, Wongsaen K, et al. Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic Of The Congo. Antimicrob Agents Chemother. 2014;58(9):5528–5536.
   PubMed Web of Science ®Google Scholar
• Worldwide antimalarial resistance network ALDISG: the effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis. 2015;15(6):692–702.
   PubMed Web of Science ®Google Scholar
• Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis. 2011;52(7):873–882.
   PubMed Web of Science ®Google Scholar
• Garner P. WorldWide antimalarial resistance network DPSG: the effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10(12):e1001564. discussion e1001564.
   PubMed Web of Science ®Google Scholar
• Byakika-Kibwika P, Ssenyonga R, Lamorde M, et al. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus dihydroartemisinin-piperaquine. BMC Infect Dis. 2019;19(1):1025.
   PubMed Web of Science ®Google Scholar
• Zongo I, Some FA, Somda SA, et al. Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine. PLoS One. 2014;9(8):e103200.
   PubMed Web of Science ®Google Scholar
• Sambol NC, Yan L, Creek DJ, et al. Population pharmacokinetics of piperaquine in young Ugandan children treated with dihydroartemisinin-piperaquine for uncomplicated malaria. Clin Pharmacol Ther. 2015;98(1):87–95.
   PubMed Web of Science ®Google Scholar
• Hoglund RM, Workman L, Edstein MD, et al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med. 2017;14(1):e1002212.
   PubMed Web of Science ®Google Scholar
• Zani B, Gathu M, Donegan S, et al. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;(1):CD010927.
   PubMed Web of Science ®Google Scholar
• Terlouw DJ, Nahlen BL, Courval JM, et al. Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. Antimicrob Agents Chemother. 2003;47(9):2929–2932.
   PubMed Web of Science ®Google Scholar
• Takechi M, Matsuo M, Ziba C, et al. Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. Trop Med Int Health. 2001;6(6):429–434.
   PubMed Web of Science ®Google Scholar
• Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet. 2002;360(9350):2031–2038.
   PubMed Web of Science ®Google Scholar
• Atroosh WM, Al-Mekhlafi HM, Snounou G, et al. Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes. Malar J. 2016;15(1):295.
   PubMedGoogle Scholar
• Obonyo CO, Ochieng F, Taylor WR, et al. Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003;97(5):585–591.
   PubMed Web of Science ®Google Scholar
• Abacassamo F, Enosse S, Aponte JJ, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health. 2004;9(2):200–208.
   PubMed Web of Science ®Google Scholar
• Warsame M, Hassan AM, Barrette A, et al. Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles. Trop Med Int Health. 2015;20(4):510–517.
   PubMed Web of Science ®Google Scholar
• Priotto G, Kabakyenga J, Pinoges L, et al. Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003;97(3):325–330.
   PubMed Web of Science ®Google Scholar
• Kayentao K, Doumbo OK, Penali LK, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11(1):364.
   PubMedGoogle Scholar
• Tona Lutete G, Mombo-Ngoma G, Assi SB, et al. Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study. PLoS Med. 2021;18(6):e1003669.
   PubMed Web of Science ®Google Scholar
• Sagara I, Beavogui AH, Zongo I, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16(2):189–198.
   PubMed Web of Science ®Google Scholar
• Simpson JA, Price R, ter Kuile F, et al. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther. 1999;66(5):472–484.
   PubMed Web of Science ®Google Scholar
• Ramharter M, Kurth FM, Belard S, et al. Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother. 2007;60(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Adamcova M, Regep L, et al. Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data. Malar J. 2011;10(1):292.
   PubMedGoogle Scholar
• Fryauff DJ, Owusu-Agyei S, Utz G, et al. Mefloquine treatment for uncomplicated falciparum malaria in young children 6-24 months of age in northern Ghana. Am J Trop Med Hyg. 2007;76(2):224–231.
   PubMed Web of Science ®Google Scholar
• Slutsker LM, Khoromana CO, Payne D, et al. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ. 1990;68(1):53–59.
   PubMed Web of Science ®Google Scholar
• Oyakhirome S, Potschke M, Schwarz NG, et al. Artesunate–amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J. 2007;6(1):29.
   PubMedGoogle Scholar
• Nhama A, Bassat Q, Enosse S, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014;13(1):309.
   PubMedGoogle Scholar
• Grandesso F, Bachy C, Donam I, et al. Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria among children under five in Bongor and Koumra, Chad. Trans R Soc Trop Med Hyg. 2006;100(5):419–426.
   PubMed Web of Science ®Google Scholar
• Anyorigiya TA, Castel S, Mauff K, et al. Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. Malar J. 2021;20(1):18.
   PubMed Web of Science ®Google Scholar
• Hietala SF, Bhattarai A, Msellem M, et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn. 2007;34(5):669–686.
   PubMed Web of Science ®Google Scholar
• Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8(1):203.
   PubMedGoogle Scholar
• Valecha N, Phyo AP, Mayxay M, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One. 2010;5(7):e11880.
   PubMed Web of Science ®Google Scholar
• Marwa K, Kapesa A, Baraka V, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: a systematic review and meta-analysis. PLoS One. 2022;17(3):e0264339.
   PubMed Web of Science ®Google Scholar
• Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2(5):e20.
   PubMedGoogle Scholar
• Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009;4(11):e7871.
   PubMed Web of Science ®Google Scholar
• Artemisinin-based combinations study G F, Beeson JG. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8(11):e1001119.
   PubMed Web of Science ®Google Scholar
• Arinaitwe E, Sandison TG, Wanzira H, et al., Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis. 2009;49(11): 1629–1637.
   PubMed Web of Science ®Google Scholar
• Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;(3):CD007483.
   PubMed Web of Science ®Google Scholar
• Jittamala P, Pukrittayakamee S, Ashley EA, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59(1):505–513.
   PubMed Web of Science ®Google Scholar
• Kurth F, Belard S, Adegnika AA, et al. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis. 2010;10(2):125–132. • Summary of current knowledge on the benefit of a paediatric ACT formula.
   PubMed Web of Science ®Google Scholar
• Sowunmi A, Akano K, Ayede AI, et al. Therapeutic efficacy and effects of artesunate-amodiaquine and artemether-lumefantrine on malaria-associated anaemia in Nigerian children aged two years and under. Infect Dis Poverty. 2016;5(1):70.
   PubMedGoogle Scholar
• Gargano N, Madrid L, Valentini G, et al. Efficacy and tolerability outcomes of a phase II, randomized, open-label, multicenter study of a new water-dispersible pediatric formulation of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in African Infants. Antimicrob Agents Chemother. 2018;62(1). DOI:10.1128/AAC.00596-17.
   PubMed Web of Science ®Google Scholar
• Frey SG, Chelo D, Kinkela MN, et al. Artesunate-mefloquine combination therapy in acute Plasmodium falciparum malaria in young children: a field study regarding neurological and neuropsychiatric safety. Malar J. 2010;9(1):291.
   PubMedGoogle Scholar
• Tietche F, Chelo D, Mina Ntoto NK, et al. Tolerability and efficacy of a pediatric granule formulation of artesunate-mefloquine in young children from Cameroon with uncomplicated falciparum malaria. Am J Trop Med Hyg. 2010;82(6):1034–1040.
   PubMed Web of Science ®Google Scholar
• Luxemburger C, Price RN, Nosten F, et al. Mefloquine in infants and young children. Ann Trop Paediatr. 1996;16(4):281–286.
   PubMed Web of Science ®Google Scholar
• Creek D, Bigira V, Arinaitwe E, et al. Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Am J Trop Med Hyg. 2010;83(4):873–875. • Study on tolerability of A-L and DHA-P in young infants specifically.
   PubMed Web of Science ®Google Scholar
• Falade CO, Ogundele AO, Yusuf BO, et al. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health. 2008;13(5):635–643.
   PubMed Web of Science ®Google Scholar
• Falade CO, Dada-Adegbola HO, Ogunkunle OO, et al. Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo) for the treatment of acute uncomplicated malaria in Nigerian children. Med Princ Pract. 2014;23(3):204–211.
   PubMed Web of Science ®Google Scholar
• Djalle D, Njuimo SP, Manirakiza A, et al. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.
   PubMed Web of Science ®Google Scholar
• Ashley EA, Lwin KM, McGready R, et al. An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Trop Med Int Health. 2006;11(11):1653–1660.
   PubMed Web of Science ®Google Scholar
• Belard S, Ramharter M, Kurth F. Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children. Cochrane Database Syst Rev. 2020;12:CD009568.
   PubMedGoogle Scholar
• Karunajeewa H, Lim C, Hung TY, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol. 2004;57(1):93–99.
   PubMed Web of Science ®Google Scholar
• Bassat Q, Ogutu B, Djimde A, et al. Tailoring a pediatric formulation of artemether-lumefantrine for treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2015;59(8):4366–4374.
   PubMed Web of Science ®Google Scholar
• Juma EA, Obonyo CO, Akhwale WS, et al. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malar J. 2008;7(1):262.
   PubMedGoogle Scholar
• Bouyou-Akotet MK, Ramharter M, Ngoungou EB, et al. Efficacy and safety of a new pediatric artesunate-mefloquine drug formulation for the treatment of uncomplicated falciparum malaria in Gabon. Wien Klin Wochenschr. 2010;122(5–6):173–178.
   PubMed Web of Science ®Google Scholar
• Abdulla S, Sagara I. Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. Malar J. 2009;8(1):S7.
   PubMedGoogle Scholar
• Banek K, Webb EL, Smith SJ, et al. Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malar J. 2018;17(1):222.
   PubMedGoogle Scholar
• Ogutu BR, Onyango KO, Koskei N, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J. 2014;13(1):33.
   PubMedGoogle Scholar
• Wirima JJ, Khormana CO, Macheso AF, et al. In vivo efficacy of quinine treatment for Plasmodium falciparum malaria in Malawian children. Ann Trop Med Parasitol. 1990;84(3):223–227.
   PubMed Web of Science ®Google Scholar
• Roche J, Guerra-Neira A, Raso J, et al. Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea). Am J Trop Med Hyg. 2003;68(5):598–601.
   PubMed Web of Science ®Google Scholar
• Obonyo CO, Juma EA. Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J. 2012;11(1):2.
   PubMedGoogle Scholar
• Ramharter M, Oyakhirome S, Klein Klouwenberg P, et al. Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial. Clin Infect Dis. 2005;40(12):1777–1784.
   PubMed Web of Science ®Google Scholar
• Song T, Chen J, Huang L, et al. Should we abandon quinine plus antibiotic for treating uncomplicated falciparum malaria? A systematic review and meta-analysis of randomized controlled trials. Parasitol Res. 2016;115(3):903–912.
   PubMed Web of Science ®Google Scholar
• Kotepui M, Kotepui KU, Milanez GD, et al. Global prevalence and mortality of severe Plasmodium malariae infection: a systematic review and meta-analysis. Malar J. 2020;19(1):274.
   PubMed Web of Science ®Google Scholar
• Rahimi BA, Thakkinstian A, White NJ, et al. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014;13(1):481.
   PubMedGoogle Scholar
• Kotepui M, Kotepui KU, Milanez GD, et al. Severity and mortality of severe Plasmodium ovale infection: a systematic review and meta-analysis. PLoS One. 2020;15(6):e0235014.
   PubMed Web of Science ®Google Scholar
• Kenangalem E, Karyana M, Burdarm L, et al. Plasmodium vivax infection: a major determinant of severe anaemia in infancy. Malar J. 2016;15(1):321.
   PubMedGoogle Scholar
• Douglas NM, Anstey NM, Buffet PA, et al. The anaemia of Plasmodium vivax malaria. Malar J. 2012;11(1):135.
   PubMedGoogle Scholar
• Langford S, Douglas NM, Lampah DA, et al. Plasmodium malariae infection associated with a high burden of anemia: a hospital-based surveillance study. PLoS Negl Trop Dis. 2015;9(12):e0004195.
   PubMed Web of Science ®Google Scholar
• Naing C, Racloz V, Whittaker MA, et al. Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. PLoS One. 2013;8(12):e78819.
   PubMed Web of Science ®Google Scholar
• Gogtay N, Kannan S, Thatte UM, et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2013;(10):CD008492.
   PubMed Web of Science ®Google Scholar
• Awab GR, Pukrittayakamee S, Imwong M, et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J. 2010;9(1):105.
   PubMedGoogle Scholar
• Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359(24):2545–2557.
   PubMed Web of Science ®Google Scholar
• Commons RJ, Simpson JA, Thriemer K, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a worldwide antimalarial resistance network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18(9):1025–1034.
   PubMed Web of Science ®Google Scholar
• Obua C, Hellgren U, Ntale M, et al. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol. 2008;65(4):493–501.
   PubMed Web of Science ®Google Scholar
• Ursing J, Eksborg S, Rombo L, et al. Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance. PLoS One. 2014;9(1):e86801.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Tensfeldt TG, Chandra R, et al. Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets. Malar J. 2014;13(1):36.
   PubMedGoogle Scholar
• Ursing J, Kofoed PE, Rodrigues A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis. 2011;203(1):109–116.
   PubMed Web of Science ®Google Scholar
• Goncalves BP, Pett H, Tiono AB, et al. Age, weight, and CYP2D6 genotype are major determinants of primaquine pharmacokinetics in African children. Antimicrob Agents Chemother. 2017;61(5). DOI:10.1128/AAC.02590-16
   Web of Science ®Google Scholar
• Vieira M, Matos Lopes TR, Mello A, et al. Doses of primaquine administered to children with Plasmodium vivax according to an age-based dose regimen. Pathog Glob Health. 2020;114(7):388–392.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Hoglund RM, Peerawaranun P, et al. Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. Malar J. 2021;20(1):366.
   PubMed Web of Science ®Google Scholar
• Setyadi A, Arguni E, Kenangalem E, et al. Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia. Malar J. 2019;18(1):111.
   PubMedGoogle Scholar
• Taylor WRJ, Thriemer K, von Seidlein L, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394(10202):929–938.
   PubMed Web of Science ®Google Scholar
• Woon SA, Manning L, Moore BR. Antimalarials for children with Plasmodium vivax infection: current status, challenges, and research priorities. Parasitol Int. 2022;87:102512.
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, et al. Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opin Pharmacother. 2022;23(7):1–10.
   Web of Science ®Google Scholar
• Velez ID, Hien TT, Green JA, et al. Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial. Lancet Child Adolesc Health. 2022;6(2):86–95.
   PubMedGoogle Scholar
• Lesko CR, Arguin PM, Newman RD. Congenital malaria in the United States: a review of cases from 1966 to 2005. Arch Pediatr Adolesc Med. 2007;161(11):1062–1067.
   PubMedGoogle Scholar
• Uneke, Uneke CJ. Congenital malaria: an overview. Tanzania Journal of Health Research. 2011;13(3). doi: 10.4314/thrb.v13i3.67615
   Google Scholar
• Alao MJ, Gbadoe AD, Meremikwu M, et al. Plasmodium falciparum malaria in infants under 5 kg: retrospective surveillance of hospital records in five sub-saharan African countries. J Trop Pediatr. 2013;59(2):154–159.
   PubMed Web of Science ®Google Scholar
• Poespoprodjo JR, Hasanuddin A, Fobia W, et al. Severe congenital malaria acquired in utero. Am J Trop Med Hyg. 2010;82(4):563–565.
   PubMed Web of Science ®Google Scholar
• Prior AR, Prata F, Mouzinho A, et al. Congenital malaria in a European country. BMJ Case Rep. 2012;2012(dec11 1):bcr2012007310–bcr2012007310.
   PubMedGoogle Scholar
• Kajoba D, Ivan Egesa W, Jean Petit H, et al. Congenital malaria in a 2-day-old neonate: a case report and literature review. Case Rep Infect Dis. 2021;2021:9960006.
   PubMed Web of Science ®Google Scholar
• Olupot-Olupot P, Eregu EIE, Naizuli K, et al. Neonatal and congenital malaria: a case series in malaria endemic eastern Uganda. Malar J. 2018;17(1):171.
   PubMedGoogle Scholar
• Quinn. Congenital malaria: a report of four cases and a review. 1982.
   Google Scholar
• Opare DA. Congenital malaria in newborn twins. Ghana Med J. 2010;44(2):76–78.
   PubMedGoogle Scholar
• KAF/lumefantrine. Medicine for malaria venture, 2018, available at: https://www.mmv.org/newsroom/interviews/kaflumefantrine accessed 27 July 2022
   Google Scholar
• Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria, ClinicalTrials.gov, Novartis Pharmaceuticals, 2022, Available at: https://clinicaltrials.gov/ct2/show/NCT03167242, accessed 2022 Jun 27
   Google Scholar
• Pharmacokinetics, Safety. Tolerability and efficacy of a new artemether-lumefantrine dispersible tablet in infants and neonates;5 kg body weight with acute uncomplicated Plasmodium falciparum malaria (CALINA), available at https://clinicaltrials.gov/ct2/show/NCT04300309, accessed 2022 sep 12
   Google Scholar